The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
about
5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j miceThe 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivoPatient considerations in the management of chronic constipation: focus on prucaloprideSerotonin transporter variant drives preventable gastrointestinal abnormalities in development and function.Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogsSelective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the ratIncreased cholinergic contractions of jejunal smooth muscle caused by a high cholesterol diet are prevented by the 5-HT4 agonist--tegaserod.Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis.Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysisPreliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study.Prucalopride: the evidence for its use in the treatment of chronic constipation.Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissuePrucalopride for constipation.Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disordersRandomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 studyChallenges and prospects for pharmacotherapy in functional gastrointestinal disorders.Emerging treatments for irritable bowel syndrome.The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties.Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development.Diagnosis and treatment of chronic constipation--a European perspective.Pharmacology of serotonin: what a clinician should know.The effects of prucalopride on postoperative ileus in guinea pigs.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Novel pharmacological therapies for management of chronic constipation.Prucalopride: a new drug for the treatment of chronic constipation.Effects of prucalopride on esophageal secondary peristalsis in humans.Existing and emerging therapies for irritable bowel syndrome.Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation.Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments.Prucalopride: a review of its use in the management of chronic constipation.New pharmacological treatment options for chronic constipation.Efficacy and safety of prucalopride in adults and children with chronic constipation.Prucalopride: A Review in Chronic Idiopathic Constipation.Gastrointestinal dysmotility disorders in critically ill dogs and cats.Radiosynthesis and preclinical evaluation of [11C]prucalopride as a potential agonist PET ligand for the 5-HT4 receptor.Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract.5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphé nucleus 5-HT neuronal activity.Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group.The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers.
P2860
Q24564961-49A0F48A-84CF-477B-8EA4-736B6AFC98F4Q24671423-BE2C5257-2E2F-4ECC-87CA-A686AB71F861Q26741304-E085575D-37CB-40A5-A72B-070F9BBD4E07Q27329816-AACC275E-9677-46BD-984A-4E12364FF278Q28203992-F0683CAE-1AB8-438D-98DB-581535228636Q28472928-99C1531C-E48B-4B3D-ADA7-6357FC9DDA0FQ33234896-EF372842-54E0-41B1-8C90-90AFA72BC54DQ33461315-08B6BC11-1F90-42CF-9B56-4CC65551B93AQ33695505-73866E41-AFCD-4E3D-BFEE-211F4824430AQ33816342-3E8782C4-7D84-46EA-9DF4-993F893BB061Q33973983-9590D809-E7FE-4FA5-BFD1-0AE4C03EED30Q34013048-F3ED9676-D595-48C0-9153-8242FD3FC58FQ34094831-E14CD9B0-3682-4566-9BCC-06690A63839DQ34166903-0163161E-2E72-40D3-AE5A-C945D63D66EBQ34230555-6BC982F0-9495-4150-9BDE-3684E6E77407Q34409219-90AA968A-A8E2-405D-9CC7-391C5D37ABD6Q34482014-536D909B-1BEE-4B43-9CE4-DBB4AD5FA102Q35025872-A128E8D5-5100-4FC6-B3B0-0F8335B44DFBQ35026383-BB21529E-5CB3-4D42-BE46-DAEB84FDB658Q35098633-F3BFDB42-5341-4CCD-B90B-69C63FC8703AQ35207439-2B8E2FB0-ADEC-4A04-81C7-E38AE75F005FQ35596862-242947E0-F107-47BA-9C9F-1EE8D1F90604Q36872925-54D770A0-8797-4BFF-8586-A991261CC392Q37164063-CC3A79CE-19A2-4EFA-BDF4-D8A502A979F4Q37394824-8582AF02-2B1A-4ACB-9C09-9F3941B35CA5Q37578493-75F3B813-276F-47B1-AA06-3E98C53981C9Q37620320-34EE608C-5DDD-432B-A075-6110ED153150Q37857849-4829CB88-645F-4959-9E7D-FAEB30796CEFQ38044067-150EE4A0-80A0-4CA3-B33C-2616522937D7Q38083079-292EE141-1E19-46BD-8167-C651CAE2F760Q38160205-ECB9B62C-4561-4C2C-AAAF-526586344DD6Q38198743-30420AD6-70BD-4F01-8FEA-4F640E4A639BQ38300258-1B882D9E-9D2F-47D6-BECB-C665FEC8BB84Q38656212-B6A3E21C-9B50-422E-84D5-8B43CF1E28AAQ38715379-E99BA365-402C-4C43-8D5E-18B43E892A4BQ39773785-9F588181-9627-47CB-B3BE-F02088E21078Q41583729-26E53C62-013F-4610-8465-F6BF3A4E3500Q42526750-6B31996A-F36E-466D-BC3F-DD5E0485820DQ43062741-40EFED3E-B887-4CD8-B3E4-60806DA750CCQ43351740-D4DF14E1-5479-4F5A-9AB7-A9F8C7C47A44
P2860
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
@ast
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
@en
type
label
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
@ast
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
@en
prefLabel
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
@ast
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
@en
P2093
P1476
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
@en
P2093
Bosmans JP
Briejer MR
Schuurkes JA
Van Daele P
P356
10.1016/S0014-2999(01)01087-1
P407
P577
2001-06-01T00:00:00Z